Literature DB >> 26203059

Discovery of T-Cell Infection and Apoptosis by Middle East Respiratory Syndrome Coronavirus.

Tianlei Ying1, Wei Li2, Dimiter S Dimitrov2.   

Abstract

Entities:  

Keywords:  DPP4; IFN; MERS-CoV; T cell; apoptosis; cytokine/chemokine; immunopathology

Mesh:

Year:  2015        PMID: 26203059      PMCID: PMC4760413          DOI: 10.1093/infdis/jiv381

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


× No keyword cloud information.
The Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with the highest mortality rate among the 6 known human coronaviruses. As of 26 June 2015, 1356 laboratory-confirmed cases have been reported to the World Health Organization, including at least 484 related deaths (ie, average mortality rate, approximately 36%), which is more than 3 times the mortality rate associated with severe acute respiratory syndrome CoV (SARS-CoV) [1]. Why the mortality rate due to MERS-CoV infection is so high is unclear. In the current issue of The Journal of Infectious Diseases, Hin Chu et al provided a clue to elucidate the high pathogenicity of MERS-CoV. This is a challenging task because the pathogenicity of MERS-CoV is complicated with numerous factors involved. In addition, the lack of human autopsy data further complicates the task. However, there are a number of similarities between the pathologies caused by MERS-CoV and those caused by SARS-CoV, as well as significant differences, as recently reviewed elsewhere [2, 3]. In both cases, the immune system plays a pivotal role, but it is differentially affected by the two viruses. The links between human immunity and MERS-CoV infection and progression have been well established. Like SARS-CoV infections, MERS-CoV infections occur more frequently in immunocompromised individuals, and patients who survive MERS-CoV infection usually have better immune responses than those who die [4]. MERS-CoV can occasionally be detected in patients' blood and urine, and MERS-CoVinfected patients have substantial abnormal hematological findings, including elevated leukocyte numbers and lymphopenia, thrombocytopenia, and coagulopathy [5], suggesting virus infiltration of circulating blood and lymphoid cells. Dysregulation of cytokines and chemokines can also be observed in MERS-CoVinfected patients [3]. These findings suggest that invasion of the human immune system, followed by the dysregulation of cytokines, might aggravate MERS-CoV infection. A well-orchestrated innate and adaptive immune response is a prerequisite for effective defense against most viral infections. MERS-CoV uses various methods to inhibit host antiviral innate immune responses. First, MERS-CoV papain-like nsp3, accessory proteins 4a, 4b, 5, and M protein could antagonize interferon α/β (IFN-α/β) expression by either binding to cytosolic pattern-recognition receptors or interfering with the downstream transcription factors [6-8]. MERS-CoV markedly decreases antiviral IFN levels in primary human lower respiratory tract cell lines and bronchial epithelium [9]. Patients with fatal MERS usually express fewer type I IFNs than those who survive [10]. Second, MERS-CoV can directly infect and replicate productively in macrophages [11] and dendritic cells [12], which results in dysregulations in the cytokine and antigen-presentation pathways. Finally, MERS-CoV could persistently induce the expression of proinflammatory cytokines which are associated with chemotaxis and activation of neutrophils associated with peripheral damage to the surrounding or distant uninfected tissues [10]. Therefore, MERS-CoV could antagonize or dysregulate human innate immunosurveillance on multiple levels. For adaptive immunity, the important roles of T cells in the surveillance and clearance of MERS-CoV have been well demonstrated by using Ad5-hDPP4–transduced mice deficient in T cells [13] and by using an immunosuppressed rhesus macaques model [14]. Indeed, the MERS-CoV infection site could recruit T cells by secretion of monocyte chemoattractant protein 1, CXCL10, and interleukin 10 stimulated by type I IFN. However, the expression of these cytokines is uncontrolled, and their persistent expression will inhibit the expression of interleukin 12 and IFN-γ, which are required for the activation of T-helper cells [10]. This, along with the downregulation of antigen-presentation pathways (decreased levels of major histocompatibility complex class I and II costimulatory molecules) as demonstrated in MERS-CoV-infected Calu-3 cells [15], would strongly inhibit the activation of T cells. Therefore, T cells are sequestered in the infected tissues but fail to be activated to target the virus. These T cells, according to the elegant study by Hin Chu et al, are highly susceptible to MERS-CoV infection and the subsequent MERS-CoV-induced apoptosis. By elaborate in vitro, ex vivo, and animal studies, the authors unambiguously showed that MERS-CoV but not SARS-CoV could effectively infect both CD4+ and CD8+ T cells from human peripheral blood mononuclear cells, human lymphoid organs (tonsil and spleen), and the spleen of the infected common marmosets. Consequently, the infiltrated T cells undergo substantial apoptosis involving intrinsic and extrinsic apoptotic pathways, although their infection by MERS-CoV seems to be abortive. Their seminal findings could give a novel perspective for the immunopathogenesis of MERS-CoV and could partly explain the lymphopenia observed in MERS-CoVinfected patients. The inability of the SARS-CoV to infect T cells may be ascribed to the lower angiotensin-converting enzyme 2 expression in T cells, which may provide a mechanism that helps explain why MERS-CoV infection causes more-severe immunological manifestations, a poorer clinical prognosis, and a higher mortality rate than SARS-CoV infections. An interesting observation by Hin Chu et al is the significant downregulation of DPP4 by MERS-CoV infection, which may further impair T-cell functions, since DPP4 is believed to play important roles in T cells signaling, transduction, activation, and costimulation [16]. In addition, this result may hint that MERS-CoV infection of T cells probably involves endocytic pathways via the endosome but not via direct plasma membrane fusion. The endocytic pathway will cointernalize DPP4 with MERS-CoV S protein into the endosome, which could explain the decreased surface associated DPP4 after infection. This endosome-dependent pathway for T cells contrasts with other cell types, such as human lung epithelial cells, in which MERS-CoV could directly transport itself across the cell membrane after binding of the viral spike glycoprotein to DPP4 [17]. These different pathways for viral entry may be associated with different IFN secretion profiles [18]. Another interesting finding is that the intrinsic and extrinsic apoptotic pathways are both activated in MERS-CoVinfected T cells. For Vero E6 cells, which are used as effective producers of MERS-CoV progeny, the MERS-CoV–induced apoptosis is gradual and dependent on effective MERS-CoV replication. In contrast to the apoptosis of Vero E6 cells, MERS-CoV–induced T-cell apoptosis seems to be independent of virus replication. The apoptosis involves activation of the extrinsic and intrinsic apoptosis pathways, which might be important in the pathogenesis of MERS. The study by Hin Chu et al highlights several important areas for future research. First, to what extent does apoptosis of T cells contribute to increased mortality? This question is difficult to answer in the absence of animal models that closely resemble the pathology seen in humans, although common marmosets could be useful in this regard. Second, the detailed apoptotic pathways could be further investigated, which would facilitate the development of antiapoptotic therapeutic reagents. Third, since T cells could be a major source of cytokines and chemokines, the cytokine profiles of T cells during MERS-CoV infection could be scrutinized and the results correlated with the severe cytokine release syndrome observed in patients with MERS. Finally, the study showed that CD4+ helper T cells are more susceptible to MERS-CoV infection, which could be related to impairment of B-cell function. An interesting question is whether the number of CD4+ T cells declines. A certain parallel could be made with acute human immunodeficiency virus type 1 infection, in which the number of CD4+ T cells in the blood declines, likely owing to their killing by the virus and cell redistribution. Clarification of these questions would allow further dissection of the complex MERS-CoV pathogenesis, with important implications for the development of therapeutics and vaccines.
  16 in total

1.  CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO.

Authors:  T Ishii; K Ohnuma; A Murakami; N Takasawa; S Kobayashi; N H Dang; S F Schlossman; C Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

2.  Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.

Authors:  Kazuya Shirato; Miyuki Kawase; Shutoku Matsuyama
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

3.  Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist.

Authors:  Daniela Niemeyer; Thomas Zillinger; Doreen Muth; Florian Zielecki; Gabor Horvath; Tasnim Suliman; Winfried Barchet; Friedemann Weber; Christian Drosten; Marcel A Müller
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

4.  High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus.

Authors:  Vivian A Scheuplein; Janna Seifried; Anna H Malczyk; Lilija Miller; Lena Höcker; Júlia Vergara-Alert; Olga Dolnik; Florian Zielecki; Björn Becker; Ingo Spreitzer; Renate König; Stephan Becker; Zoe Waibler; Michael D Mühlebach
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

5.  Middle east respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response.

Authors:  Kam-Leung Siu; Man Lung Yeung; Kin-Hang Kok; Kit-San Yuen; Chun Kew; Pak-Yin Lui; Chi-Ping Chan; Herman Tse; Patrick C Y Woo; Kwok-Yung Yuen; Dong-Yan Jin
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

6.  Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus.

Authors:  Florian Zielecki; Michaela Weber; Markus Eickmann; Larissa Spiegelberg; Ali Moh Zaki; Mikhail Matrosovich; Stephan Becker; Friedemann Weber
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

7.  The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists.

Authors:  Yang Yang; Ling Zhang; Heyuan Geng; Yao Deng; Baoying Huang; Yin Guo; Zhengdong Zhao; Wenjie Tan
Journal:  Protein Cell       Date:  2013-12-08       Impact factor: 14.870

8.  Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus.

Authors:  Laurence Josset; Vineet D Menachery; Lisa E Gralinski; Sudhakar Agnihothram; Pavel Sova; Victoria S Carter; Boyd L Yount; Rachel L Graham; Ralph S Baric; Michael G Katze
Journal:  mBio       Date:  2013-04-30       Impact factor: 7.867

9.  Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?

Authors:  Emmanuel Faure; Julien Poissy; Anne Goffard; Clement Fournier; Eric Kipnis; Marie Titecat; Perinne Bortolotti; Laura Martinez; Sylvain Dubucquoi; Rodrigue Dessein; Philippe Gosset; Daniel Mathieu; Benoit Guery
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

10.  Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.

Authors:  Abdullah Assiri; Jaffar A Al-Tawfiq; Abdullah A Al-Rabeeah; Fahad A Al-Rabiah; Sami Al-Hajjar; Ali Al-Barrak; Hesham Flemban; Wafa N Al-Nassir; Hanan H Balkhy; Rafat F Al-Hakeem; Hatem Q Makhdoom; Alimuddin I Zumla; Ziad A Memish
Journal:  Lancet Infect Dis       Date:  2013-07-26       Impact factor: 25.071

View more
  19 in total

1.  Clinical and immunological features of severe and moderate coronavirus disease 2019.

Authors:  Guang Chen; Di Wu; Wei Guo; Yong Cao; Da Huang; Hongwu Wang; Tao Wang; Xiaoyun Zhang; Huilong Chen; Haijing Yu; Xiaoping Zhang; Minxia Zhang; Shiji Wu; Jianxin Song; Tao Chen; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 2.  The Immune Responses against Coronavirus Infections: Friend or Foe?

Authors:  Arefe Vafaeinezhad; Mohammad Reza Atashzar; Rasoul Baharlou
Journal:  Int Arch Allergy Immunol       Date:  2021-05-05       Impact factor: 2.749

Review 3.  Human Coronaviruses: A Review of Virus-Host Interactions.

Authors:  Yvonne Xinyi Lim; Yan Ling Ng; James P Tam; Ding Xiang Liu
Journal:  Diseases       Date:  2016-07-25

Review 4.  Coronavirus infection and immune system: An insight of COVID-19 in cancer patients.

Authors:  Alice Indini; Erika Rijavec; Michele Ghidini; Claudia Bareggi; Monica Cattaneo; Barbara Galassi; Donatella Gambini; Francesco Grossi
Journal:  Crit Rev Oncol Hematol       Date:  2020-07-09       Impact factor: 6.312

Review 5.  Lymphopenia in COVID-19: Therapeutic opportunities.

Authors:  Nazanin Fathi; Nima Rezaei
Journal:  Cell Biol Int       Date:  2020-06-03       Impact factor: 3.612

6.  Hypercytokinemia and Pathogen-Host Interaction in COVID-19.

Authors:  Alaa Badawi
Journal:  J Inflamm Res       Date:  2020-06-23

Review 7.  The molecular virology of coronaviruses.

Authors:  Ella Hartenian; Divya Nandakumar; Azra Lari; Michael Ly; Jessica M Tucker; Britt A Glaunsinger
Journal:  J Biol Chem       Date:  2020-07-13       Impact factor: 5.157

8.  Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome.

Authors:  David K Meyerholz; Allyn M Lambertz; Paul B McCray
Journal:  Am J Pathol       Date:  2015-11-18       Impact factor: 4.307

Review 9.  Modulation of the immune response by Middle East respiratory syndrome coronavirus.

Authors:  Somayeh Shokri; Shahab Mahmoudvand; Reza Taherkhani; Fatemeh Farshadpour
Journal:  J Cell Physiol       Date:  2018-08-26       Impact factor: 6.384

10.  Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients.

Authors:  Jae-Hoon Ko; Ga Eun Park; Ji Yeon Lee; Ji Yong Lee; Sun Young Cho; Young Eun Ha; Cheol-In Kang; Ji-Man Kang; Yae-Jean Kim; Hee Jae Huh; Chang-Seok Ki; Byeong-Ho Jeong; Jinkyeong Park; Chi Ryang Chung; Doo Ryeon Chung; Jae-Hoon Song; Kyong Ran Peck
Journal:  J Infect       Date:  2016-08-09       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.